Inhibition of p38 MAPK or immunoproteasome overcomes resistance of chronic lymphocytic leukemia cells to Bcl-2 antagonist venetoclax

Inhibition of p38 MAPK or immunoproteasome overcomes resistance of chronic lymphocytic leukemia cells to Bcl-2 antagonist venetoclax

Abstract Chronic lymphocytic leukemia (CLL) is a hematological neoplasm of CD19-positive mature-appearing B lymphocytes. Despite the clinical success of targeted therapies in CLL, the development of resistance diminishes their therapeutic activity. This is also true for the Bcl-2 antagonist venetocl...

Full description

Bibliographic Details
Main Authors: Damjan Avsec, Marja Škrlj Miklavčič, Tilen Burnik, Maša Kandušer, Maruša Bizjak, Helena Podgornik, Irena Mlinarič-Raščan
Format: Article
Language:English
Published: Nature Publishing Group 2022-10-01
Series:Cell Death and Disease
Online Access:https://doi.org/10.1038/s41419-022-05287-6

Internet

https://doi.org/10.1038/s41419-022-05287-6

Similar Items